To our knowledge, this is the first study to compile and compare data from all FDA registration trials for medications approved to treat adult ADHD. This article describes a process by which readily available adverse event reporting data can be used as a tool to inform shared clinical decision-making. While differences in the methodology and outcome reporting of the trials included may limit generalizability, the number of individual patients included and the completeness of the discontinuation data can be used to inform discussions with patients about the relative likelihood of adverse experiences and other patient concerns.
Keyphrases
- end stage renal disease
- ejection fraction
- newly diagnosed
- chronic kidney disease
- attention deficit hyperactivity disorder
- electronic health record
- autism spectrum disorder
- healthcare
- decision making
- prognostic factors
- peritoneal dialysis
- big data
- mental health
- emergency department
- patient reported outcomes
- combination therapy